Application | Comment | Organism |
---|---|---|
drug development | targeted inhibition of PLA2- and autotaxin-mediated lysophosphatidic acid synthesis may be a potential strategy for the prevention of nerve injury-induced neuropathic pain | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
arachidonyl trifluoromethyl ketone | AACOCF3, both de novo lysophosphatidic acid production and neuropathic pain-like behaviors are substantially abolished by intrathecal injection of arachidonyl trifluoromethyl ketone, a mixed inhibitor of cPLA2 and iPLA2, at 1 h after injury | Mus musculus | |
bromoenol lactone | both de novo lysophosphatidic acid production and neuropathic pain-like behaviors are substantially abolished by intrathecal injection of bromoenol lactone, an iPLA2 inhibitor, at 1 h after injury | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
male C57BL/6J mice | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
spinal cord | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
arachidonyl thio-PC + H2O | - |
Mus musculus | arachidonic acid + (7R)-4-hydroxy-N,N,N-trimethyl-7-sulfanyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide | - |
? |
Synonyms | Comment | Organism |
---|---|---|
calcium-independent phospholipase A2 | - |
Mus musculus |
cPLA2 | - |
Mus musculus |
cytosolic phospholipase A2 | - |
Mus musculus |
iPLA2 | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
physiological function | PLA2- and autotaxin-mediated de novo lysophosphatidic acid production in the early phase is involved in nerve injury-induced neuropathic pain | Mus musculus |